Shibani Sircar Kurian on where to look now in IT and pharma
"In the case of IT, the nature of deals have changed and are now more tilted toward cost take outs which favour largecap IT. So our stance on IT remains somewhat cautious. Of course, valuations have corrected quite sharply and at this point in time we prefer largecap over midcap IT."